AlloVir, Inc. (NASDAQ:ALVR – Get Rating) General Counsel Edward Miller sold 2,032 shares of AlloVir stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $5.08, for a total transaction of $10,322.56. Following the sale, the general counsel now directly owns 148,999 shares in the company, valued at approximately $756,914.92. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Edward Miller also recently made the following trade(s):
- On Monday, November 14th, Edward Miller sold 2,358 shares of AlloVir stock. The shares were sold at an average price of $8.91, for a total transaction of $21,009.78.
AlloVir Price Performance
Shares of NASDAQ ALVR opened at $5.13 on Tuesday. AlloVir, Inc. has a 1 year low of $3.17 and a 1 year high of $10.29. The stock has a market cap of $477.93 million, a P/E ratio of -1.83 and a beta of 0.87. The firm has a 50-day moving average of $6.23 and a 200 day moving average of $6.94.
Wall Street Analysts Forecast Growth
Separately, SVB Leerink lowered their price target on shares of AlloVir from $25.00 to $19.00 and set an “outperform” rating for the company in a research report on Monday.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Amalgamated Bank purchased a new position in AlloVir in the first quarter worth about $33,000. Corton Capital Inc. purchased a new position in AlloVir in the second quarter worth about $41,000. SG Americas Securities LLC purchased a new position in AlloVir in the second quarter worth about $49,000. Denali Advisors LLC purchased a new position in AlloVir in the third quarter worth about $51,000. Finally, GMT Capital Corp raised its holdings in AlloVir by 66.2% in the second quarter. GMT Capital Corp now owns 1,891,170 shares of the company’s stock worth $7,376,000 after buying an additional 753,100 shares during the last quarter.
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
- Get a free copy of the StockNews.com research report on AlloVir (ALVR)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.